Objective: To analyze the pharmaceutical intervention effect of prophylactic antibiotics in type I incisions. Methods: A total of 3 899 patients undergoing type I incision surgery in a hospital from January 1 to December 31, 2018, were selected as the group before the pharmaceutical intervention, and 4 346 patients from January 1 to December 31, 2019, as the group after pharmaceutical intervention. The proportion and rationality of prophylactic antibiotics were compared between the two groups. Results: Compared with those before the pharmaceutical intervention, the proportion and rationality of prophylactic antibiotics, selection of antibiotic varieties, and rationality of drug course in type I incisions were significantly improved after pharmaceutical intervention (P < 0.05). Conclusion: Pharmaceutical intervention can reduce the proportion of prophylactic antibiotics in type I incisions and improve the rationality of prophylactic antibiotics.

[1] National Health and Family Planning Commission; National Administration of Traditional Chinese Medicine; Ministry of Health, General Logistics Department of the PLA. Guiding Principle of Clinical Application of Antibacterials[Z]. GWBYF (2015) No. 43.

[2] Department of Medical Administration, Ministry of Health. Notice on National Special Rectification for Clinical Use of Antibacterial Drugs[Z]. GWBYZF (2011) No. 56.

[3] Zhou WJ, Luo ZN, Tang CM, et al. Is there an improvement of antibiotic use in China? Evidence from the usage analysis of combination antibiotic therapy for type I incisions in 244 hospitals[J]. J Huazhong Univ Sci Technolog Med Sci, 2016, 36(5):772- 779, https://doi.org/10.1007/s11596-016-1660-1.

[4] National Health and Family Planning Commission of the People’s Republic of China. Notice of the General Office of the Ministry of Health on Continuing In-depth Implementation of National Special Rectification for Clinical Use of Antibacterial Drugs [EB/OL]. http://www.moh.gov.cn/mohyzs/s3586/201203/54251.shtml.2012-3-6.

[5] Medical Administration Bureau, National Health and Family Planning Commission; Expert Committee on Rational Drug Use, National Health and Family Planning Commission. National Guidelines for Antimicrobial Therapy[M]. 2nd Edition. Beijing: People’s Medical Publishing House, 2017:130-134.

[6] Written by (US) David N Gilbert, Henry F Chambers, George M Eliopoulos, et al. The Sanford Guide to Antimicrobial Therapy[M]. 46th Edition. Translated by FAN Hongwei, et al. Beijing: Peking Union Medical College Press, 2017:200-203.

[7] CHEN Xin-qian, JIN You-yu, TANG Guang. New Materia Medica[M]. 18th Edition. Beijing: People’s Medical Publishing House, 2018:39-98.

[8] Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009- 2010 [J]. Infect Control Hosp Epidemiol, 2013, 34(1):1-14, https://doi.org/10.1086/668770.

[9] Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery[J]. Surg Infect (Larchmt), 2013, 14(1):73-156, https://doi.org/ 10.1089/sur.2013.9999.